January 24-26, 2023 | Boston, MA

The DNA damage response inhibitor space only continues to grow, with progress being accelerated by a shift in focus onto next-generation targets like PolQ and WRN, moving forward from monotherapies through combining targets and exploiting sensitivity caused by DDRis to enhance other therapies like radiotherapy.

The scope of this year’s 6th DDR Inhibitors Summit is dedicated to exploring these strategies that aim to deep dive into a comprehensive overview of the DDR space, with over 30+ world class speakers sharing insights preclinical updates, progress in the clinic, solutions to overcoming toxicity and improving patient selection.

Also join Beacon’s own DDR Research Analyst, Kieran Pinto, as he lays out the current DDRi landscape and evaluates future directions: 2023 and beyond.